ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Communication   
  • Breast Can Curr Res 2023, Vol 8(5): 5
  • DOI: 10.4172/2572-4118.1000218

Preclinical Evidence versus Clinical Outcomes in CAR and Fc-CR T Cell Immunotherapy for Breast Cancer

Asma Arriga*
Department of Breast Oncology, Italy
*Corresponding Author : Asma Arriga, Department of Breast Oncology, Italy, Email: asma.arriga_764@gmail.com

Received Date: Oct 01, 2023 / Published Date: Oct 30, 2023

Abstract

Immunotherapy, specifically Chimeric Antigen Receptor (CAR) T cell and Fc-receptor-enhanced chimeric receptor (Fc-CR) T cell therapies, has emerged as a promising approach for treating cancer. The development and translation of these therapies from preclinical studies to clinical applications represent a critical phase in their evaluation. This abstract highlights the essential aspects of the relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy for cancer. In preclinical research, CAR and Fc-CR T cells have demonstrated impressive anti-tumor efficacy, targeting a wide range of tumor antigens. However, the translation of these findings into clinical practice has brought to light a series of challenges. Factors such as tumor microenvironment, patient heterogeneity, and safety concerns have influenced the clinical performance of these therapies, often leading to outcomes that differ from preclinical expectations. This abstract explores the critical components of preclinical evidence, including in vitro and animal model studies, and their implications on clinical outcomes. It examines the discordance between preclinical promise and clinical reality, shedding light on the factors that contribute to this discrepancy. Furthermore, we discuss the strategies and ongoing efforts to bridge the gap between preclinical and clinical results, emphasizing the need for improved predictive models and patient stratification. Understanding the complex relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy is essential for advancing the field and enhancing the effectiveness of these groundbreaking cancer treatments. By addressing the challenges and optimizing the translational process, researchers and clinicians can improve the prospects of delivering innovative, personalized, and more efficacious cancer immunotherapies to patients in the future

Citation: Arriga A (2023) Preclinical Evidence versus Clinical Outcomes in CARand Fc-CR T Cell Immunotherapy for Breast Cancer. Breast Can Curr Res 8: 218. Doi: 10.4172/2572-4118.1000218

Copyright: © 2023 Arriga A. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top